Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC006836 | Panoply™ Human HAPLN4 Knockdown Stable Cell Line | Inquiry |
| CSC-SC006836 | Panoply™ Human HAPLN4 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD07328Z | Human Hapln4 adenoviral particles | Inquiry |
| LV14389L | human HAPLN4 (NM_023002) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH114113 | shRNA set against Mouse Hapln4(NM_177900.4) | Inquiry |
| SHH310325 | shRNA set against Human Hapln4 (NM_023002.2) | Inquiry |
| SHH310329 | shRNA set against Mouse Hapln4 (NM_177900.4) | Inquiry |
| SHH310333 | shRNA set against Rat Hapln4 (NM_001108398.1) | Inquiry |
| SHW009898 | shRNA set against Danio rerio HAPLN4 (NM_001044907) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFR008017 | Rat Hapln4 cDNA Clone(NM_001108398.1) | Inquiry |
| MiUTR1M-05541 | HAPLN4 miRNA 3'UTR clone | Inquiry |
| MiUTR4H-TG04090 | HAPLN4 miRNA 3'UTR clone | Inquiry |
| CDCB171373 | Danio rerio HAPLN4 ORF Clone (NM_001044907) | Inquiry |
| CDCL116021 | Human Hapln4 ORF clone (NM_177900.4) | Inquiry |
| CDCR375058 | Rat Hapln4 ORF Clone(NM_001108398.1) | Inquiry |
Recent Research Progress
HAPLN4, also known as brain-specific link protein (Bral-2), can be find throughout the neurosensory retina, with strong labeling of the nerve fiber and ganglion cell layers. According to some researches, hapln4-brevican interaction may play a key role in synaptic stabilization and the structural integrity of the Perineuronal nets (PNNs). The absence of perineuronal net formation at the end of the developmental period in the bral-2-knockout mice results in higher hearing threshold at high frequencies and weaker temporal resolution ability in adult bral-2-knockout animals compared to WT mice. Besides, HAPLN4/Bral2 is indispensable for the proper localization of brevican and the structural integrity of the PNNs in the brainstem and cerebellum. Bral2 may have a role in the organization of the PNNs, in association with brevican, that is independent of aggrecan binding. There was a heterogenous attenuation of PNNs components, including glycosaminoglycans, indicating the elaborate molecular organization of the PNNs components. Furthermore, M. Blosa indicated the change of HaPLN4 expression can be used as a biological indicator for the direct interaction between ECM and synapse. There has been more and more evidences showed that HaPLN4 may play an important role in nervous system related diseases.
A recent research validated that HAPLN4 was a direct target of miR-19b. MiR-19b, has been reported to be involved in nervous system disease including Parkinson's disease (PD), suppressed HAPLN4 expression by binding to its 3’-UTR, the complementary sequences of miR-19b, in a posttranscriptional manner. HAPLN4 has been pointed to be restricted in expression to the brain/central nervous system and be implicated in multiple brain injury disease. In the present study, the results found that over-expression of HAPLN4 dramatically accelerated cell apoptosis of MPP+-treated SH-SY5Y cells which is a PD model in vitro. According to a previous research, Moreover, the restoration of HAPLN4 expression significantly reversed miR-19b-triggered anti-apoptosis effect in MPP+-induced SH-SY5Y cells. Considering the regulatory effects of miR-19b on HAPLN4 expression, the research concluded that HAPLN4 enhanced MPP+-induced apoptosis possibly via increasing caspase 3 activity, ROS production and inflammatory responses. A recent report demonstrated that HAPLN4 showed a high expression following an injury of the brain. Also, the mutations or variants of gene HAPLN4 was reported to be associated with the pathophysiological process of essential tremor (ET). HAPLN2 and HAPLN4 are he members of the hyaluronan and proteoglycan binding link proteins. Similar to HAPLN2, current study revealed that HAPLN4 activated MAPK signaling pathway via enhancing the phosphorylation levels of ERK, JNK and p38, and HAPLN4-triggered MAPK signaling was markedly reversed by regaining of miR-19b expression. All these data implied that miR-19b abated MPP+-induced injury of SHSY5Y cells by blocking MAPK signaling pathway through targeting HAPLN4. Taken together, the neuroprotective effect of miR-19b might be mediated by HAPLN4/MAPK pathway in SH-SY5Y cells.
Interestingly, Jonathan M. Heppner has revealed HAPLN4 may be associated with the pathogenesis of tardive osteoarthritis. What’s more, the analysis of a novel framework for differential co-expression networks, developed At the Department of Biotechnology and Food Science at the Norwegian University of Science and Technology (NTNU), have recently identified HAPLN4 with Possible rheumatoid arthritis(RA)-related functions.
References: